KIF20A and neoplasm: A recent phase II trial evaluated the efficacy of the tumor antigen-based peptide cocktail vaccine OCV-C01 derived from antigen Kif20A and vascular endothelial growth factor receptors 1 and 2 (VEGFR1 and VEGFR2), in combination with gemcitabine as adjuvant treatment pancreatectomy (n = 30) (UMIN000007991) [211].